Synapse Biomedical to work with international partners to commercialize implantable neurostimulation technology

Chuck Soder - Synapse Biomedical will be working with several international partners to commercialize a fully implantable version of the neurostimulation technology that the company was founded upon. The Oberlin-based company is in the process of licensing the third-generation diaphragm pacing technology from Case Western Reserve University, said CEO Anthony Ignagni. Synapse already sells the second-generation technology. The NeuRx Diaphragm Pacing System is best known for helping the late Superman actor